Is tesamorelin FDA approved?
Yes — tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The compound is the only synthetic GHRH analogue with this approved clinical indication. Research-supply tesamorelin is sold for laboratory and bench-research applications only — the FDA approval covers the pharmaceutical product distributed through clinical-pharmacy channels, not the research-supply format.
What the research literature says
Tesamorelin’s regulatory pathway is distinct from the research-only compounds in the catalog. The compound was developed by Theratechnologies through the phase 1-2-3 clinical-trial development process and received FDA approval based on the pivotal Falutz trial in HIV-associated lipodystrophy (PMID 18057338) and the supporting clinical-pharmacology and safety data (PMID 18690162, PMID 20554713).
The Spooner pharmacotherapy review consolidates the regulatory and clinical-pharmacology framework (PMID 22298602). The Stanley work on inflammatory markers in HIV patients with excess abdominal fat extended the framing into associated metabolic-profile improvements (PMID 21516030, PMID 22495074). Long-term safety and continued-efficacy extension data was published in the Falutz long-term safety report (PMID 18690162).
The research-supply form of tesamorelin available through the Ronin catalog is supplied for laboratory and bench-research applications. The FDA-approved pharmaceutical product is distinct — distributed through clinical-pharmacy channels with the prescribing-information label specific to the approved indication. Research-supply use does not imply clinical-use authorization.
Why this matters in research context
Tesamorelin is one of the few catalog compounds with active FDA approval for a clinical indication, which provides an unusually well-characterised clinical-pharmacology backdrop for research-supply protocols. Researchers using tesamorelin in preclinical or research-only protocols can anchor experimental design to the published clinical-pharmacology profile while operating within the research-use-only framework that governs the catalog supply form.
Related compounds
- Tesamorelin 10mg — research-supply form
- Tesamorelin (glossary entry) — clinical-trial overview, mechanism, dosing
Related research questions
References
- Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-2370. [PMID 18057338]
- Falutz J et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008;22(14):1719-1728. [PMID 18690162]
- Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010;95(9):4291-4304. [PMID 20554713]
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother 2012;46(2):240-247. [PMID 22298602]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Tesamorelin is sold strictly as a research-grade reagent for laboratory and bench research applications.